

Synthesis and elaboration of functionalised carbohydrate-derived spiroketals

Peter A. V. van Hooft,^a Farid El Oualid,^b Herman S. Overkleef,^b Gijsbert A. van der Marel,^b Jacques H. van Boom^{*b} and Michiel A. Leeuwenburgh^b

^a TNO Prins Maurits Laboratory, P.O. Box 45, 2280 AA Rijswijk, The Netherlands

^b Leiden Institute of Chemistry, Leiden University, Gorlaeus Laboratories, PO Box 9502,

2300 RA Leiden, The Netherlands. E-mail: j.boom@chem.leidenuniv.nl;

Fax: +31 71 5274307; Tel: +31 71 5274280

Received 5th February 2004, Accepted 8th March 2004

First published as an Advance Article on the web 5th April 2004


The scope of a stereoselective three-step approach for the synthesis of sugar derived spiroketals is presented. The methodology consists of Grignard addition of vinyl- or allylmagnesium bromide to a carbohydrate lactone, followed by K-10 clay mediated glycosidation with a terminal alkenol and subsequent ring-closing metathesis of the resulting diene. The generality of this procedure is demonstrated by the synthesis of various pyranose- and furanose-derived spiroketals, as well as more advanced tricyclic spiroketal derivatives. It is shown that functionalisation of the double bond in the resulting spiroketals leads to fused polycyclic ethers.

Introduction

Spiroketals, particularly 1,6-dioxa-spiro[4.5]decanes and 1,7-dioxa-spiro[5.5]undecanes, which are common structural features of many natural products,¹ have attracted considerable interest from synthetic organic chemists over the past several decades. An attractive approach towards functionalised spiroketals involves the use of carbohydrates as readily available chiral synthons. For instance, Hanessian and Ugolini² reported the acid-catalysed intramolecular glycosidation of a ketose derivative to a 1,7-dioxa-spiro[5.5]undecene. Similarly, [4.4] as well as [4.5] spiroketals were produced by acid-catalysed *trans*-ketalisation of *keto*-furanosides.³ Alternatively, a 1,6-dioxa-spiro[4.5]undecane framework was constructed by radical promoted cyclisation of *C*-glycosides.⁴ However, the spiroketalisations described above lead to epimeric mixtures which require additional acid treatment to force the equilibrium to the thermodynamically most stable isomer. Sinaÿ and Haudrechy⁵ nicely evaded this drawback by predispositioning the configuration at the future spirocentre through a stereoselective glycosidation of a ketose derivative. The resulting ketoglycoside was successively converted into a spiroketal *via* radical mediated ring-closure.⁶ In line with this approach, we developed a three-step procedure,⁷ comprising Grignard addition of vinyl- or allylmagnesium bromide to perbenzylated D-gluconolactone, followed by stereoselective Montmorillonite K-10 clay⁸ mediated condensation with different terminal alkenols and subsequent formation of the spiroketal by ring-closing metathesis using Grubbs' catalyst.⁹ We present here the scope of this approach in full detail by the transformation of pyranose and furanose derived lactones into [4.4], [4.5], [4.6] and [5.5] spiroketals, as well as the synthesis of more advanced tricyclic compounds.

Results and discussion





















In a preliminary paper^{7a} we showed that 1,6-dioxa-(5*S*)-spiro[4.5]dec-3-ene **7**^{10,11} (see Scheme 1) and 1,7-dioxa-(6*S*)-spiro[5.5]undec-9-ene **8**¹¹ could be assembled with a high degree of stereoselectivity following the three-step reaction sequence mentioned above. In the first instance, fully benzylated gluconolactone **1**¹² was converted into the known¹³ α -epimer of vinylketose **2** by nucleophilic addition of vinylmagnesium bromide afforded the known¹⁴ allylketose **3** as a mixture of anomers (α : β = 4; 1). Next, Montmorillonite K-10 clay mediated glycosidation of donors **2** and **3** with an excess of allyl alcohol afforded the corresponding isomerically pure α -ketoglycosides **4** and **5**. The last step, comprising RCM of dienes **4** and **5** using Grubbs' catalyst **6** (6 mol%) in toluene at 60 °C, gave the respective spiroketal derivatives **7** and **8** in 65% and 50% overall yield from **1**. The *S*-configuration of the spirocentres in compounds **7** and **8** was unambiguously assigned by NOESY experiments (see Scheme 1).¹⁵ In addition, the NMR-data of saturated spiroketal **9**, obtained by hydrogenation of **7**



Scheme 1 Reagents and conditions: i, vinylmagnesium bromide (1.2 equiv.), Et₂O, -78 °C (**2**: 91%). ii, Allylmagnesium bromide (1.2 equiv.), Et₂O, -78 °C (**3**: 83%). iii, Allyl alcohol (6 equiv.), K-10 clay (200 mass%), 4 Å sieves, CH₂Cl₂ (**4**: 75%, **5**: 69%). iv, **6** (0.06 equiv.), toluene, 60 °C (**7**: 95%, **8**: 88%, **11**: 88%, **14**: 95%, **15**: 90%). v, PtO₂, H₂, EtOAc (85%). vi, 3-Buten-1-ol (6 equiv.), K-10 clay (200 mass%), 4 Å sieves, CH₂Cl₂ (**10**: 68%, **12**: 69%, **13**: 80%). vii, 4-Penten-1-ol (6 equiv.), K-10 clay (200 mass%), 4 Å sieves, CH₂Cl₂ (80%).

bromide afforded the known¹⁴ allylketose **3** as a mixture of anomers (α : β = 4; 1). Next, Montmorillonite K-10 clay mediated glycosidation of donors **2** and **3** with an excess of allyl alcohol afforded the corresponding isomerically pure α -ketoglycosides **4** and **5**. The last step, comprising RCM of dienes **4** and **5** using Grubbs' catalyst **6** (6 mol%) in toluene at 60 °C, gave the respective spiroketal derivatives **7** and **8** in 65% and 50% overall yield from **1**. The *S*-configuration of the spirocentres in compounds **7** and **8** was unambiguously assigned by NOESY experiments (see Scheme 1).¹⁵ In addition, the NMR-data of saturated spiroketal **9**, obtained by hydrogenation of **7**

Table 1 Examples of the K-10/RCM approach towards monosaccharide-derived spiroketals

Entry	Donor	Acceptor	K-10 product ^a	Yield (%)	RCM product ^b	Yield (%)
1	 16		 17	70	 18	90 ^c
2	 19		 20	89	 21	85 ^c
3	 22		 23	66	 24	95 ^d
4	 25		 26	54	 27	87
5	 25		 28	42	 29	99 ^c

^a Acceptor (6 equiv.), K-10 (200 mass%), 4 Å sieves, CH₂Cl₂, 20 °C. ^b **6** (0.06 equiv.), toluene, 60 °C. ^c **6** (0.06 equiv.), CH₂Cl₂, 20 °C. ^d **6** (0.03 equiv.), CH₂Cl₂, 20 °C.


under the influence of platinum(IV) oxide, were identical to those reported by the groups of Suárez and Taylor.^{44,16} Glycosidation of ketoses **2** and **3** with 3-buten-1-ol and 4-penten-1-ol and subsequent RCM as described above led to spiroketals **11**,^{2,17} **14** and **15** in 60%, 66% and 72% yields, respectively, over the two steps.^{7,11}

In the next stage, the influence of the carbohydrate configuration on the efficacy of the three-step methodology was studied. Therefore, the lactones derived from fully benzylated L-fuco- and L-rhamnopyranose^{18,19} were subjected to Grignard addition of allylmagnesium bromide and K-10 mediated glycosidation with allyl alcohol (entries 1 and 2, Table 1) as described in Scheme 1. RCM of the resulting dienes **17** and **20** using Grubbs' catalyst (6 mol%) in dichloromethane at ambient temperature afforded the respective spiroketals **18** and **21** (55% and 68%, respectively), the structures of which were fully assigned by NMR-spectroscopy. Continuing our investigation, the acid-labile furanoid 2,3;5,6-di-*O*-isopropylidene-D-manno-1,4-lactone²⁰ was subjected to the three-step sequence. Reaction of this lactone with vinylmagnesium bromide led to the isolation of the expected vinylketose **22** (entry 3) in 45% as well as a side-product. Mass spectrometric and NMR-spectroscopic analysis indicated that the latter compound resulted from double vinyl addition which led to an acyclic bis-adduct.²¹ However, subsequent glycosidation of **22** and RCM steps proceeded smoothly to give spiroketal **24** in 64% yield over two steps.


Reaction of the same lactone with allylmagnesium bromide furnished allylketose **25** in excellent yield. Subjection of **25** to K-10 glycosidation with allyl alcohol as well as 3-buten-1-ol (entries 4 and 5 respectively), followed by RCM of the resulting dienes afforded spiroketals **27** and **29** in 47% and 42% yield over two steps.

The generality of the approach is further emphasised by its application in the synthesis of the more complex tricyclic spiroketal **34**. Lactone **31** (see Scheme 2) was synthesised from known²² pyranopyran compound **30** in two steps. Liberation of the acetal function by acid hydrolysis with 3 M sulfuric acid in acetic acid at 80 °C, followed by subsequent oxidation furnished lactone **31** in 50% yield. Execution of the three-step reaction sequence on this lactone, as described for the conversion of **2** into **7**, proceeded in 20% overall yield to afford spiroketal **34**, the structure of which was ascertained by NOESY-experiments. A different tricyclic constellation, namely **37** (see Scheme 3), was accessible through K-10-mediated glycosidation of vinylketose **2** with sugar derived acceptor **35**.²³ Remarkably, this glycosidation only proceeded in satisfactory yield when **35** was used in a 20-fold excess. RCM of the resulting disaccharide **36** with Grubbs' catalyst **6** (6 mol%) furnished tricyclic adduct **37** in 64% yield.


Interestingly, yet another opportunity to construct oligocyclic systems presents itself by elaboration of the double bond in the spiroketals, as is demonstrated for spiroketal **8** (see



Scheme 2 Reagents and conditions: i, a) 3 M H₂SO₄, HOAc, 80 °C, 6 h, b) DMSO, acetic anhydride, 16 h (50%). ii, Vinylmagnesium bromide, Et₂O, -78 °C (42%). iii, Allyl alcohol (6 equiv.), K-10 clay (200 mass%), 4 Å sieves, CH₂Cl₂ (50%). iv, **6** (0.06 equiv.), CH₂Cl₂ (95%).



Scheme 3 Reagents and conditions: i, **35** (20 equiv.), K-10 clay (200 mass%), 4 Å sieves, CH₂Cl₂ (45%). ii, **6** (0.06 equiv.), CH₂Cl₂ (64%).



Scheme 4 Reagents and conditions: i, (Ph₃P)₃RhCl (cat.), DBU, EtOH, 60 °C (90%). ii, a) DMDO, CH₂Cl₂, 0 °C, b) allylmagnesium chloride, THF, 0 °C (61%). iii, Allyl bromide, NaH, DMF (93%). iv, catalyst **41** (0.5 mol%), CH₂Cl₂, Δ (80%).

Scheme 4). Conversion of **8** into enol ether **38** was effected in 90% yield by reaction with Wilkinson's catalyst²⁴ in the presence of a catalytic amount of DBU in ethanol at 60 °C.^{22a} Next, **38** was treated with a freshly prepared solution of 3,3-dimethyldioxirane (DMDO) in acetone at 0 °C,²⁵ followed by

opening of the crude epoxide with allylmagnesium bromide in THF²⁶ at 0 °C. The resulting alkenol **39** was isolated in 61% yield. Allylation under standard conditions, followed by RCM using 0.5 mol% Grubbs' catalyst **41**²⁷ in refluxing dichloromethane afforded tricyclic product **42** in 74% over two steps. The structure of **42** was confirmed by NOESY-experiments, of which the most important signals are depicted in Scheme 4.

Conclusion

In this paper, the scope of a stereoselective and versatile three-step approach towards the construction of pyranose (*D-gluco*, *L-fuco* and *L-rhamno*) and furanose (*D-manno*) derived unsaturated spiroketals is presented. The methodology has proven to be effective for the construction of [4.4], [4.5], [5.5], [5.6] and [5.7] spiroketals and also of the more advanced tricyclic compounds **34** and **37**. It was demonstrated that the double bond in the newly formed spiro system is amenable to further elaboration, to furnish fused oxacyclic compounds such as **42**. It is of interest to note that the allylic ether **42** can be subjected to the same sequence of reactions, to give entrance to a reiterative procedure.²⁸ Its broad applicability, as well as the potential to further elaborate the produced spiroketals, make this three-step methodology a valuable tool in the synthesis of natural products containing highly functionalised spiroketal moieties.

Experimental

General

Dichloromethane, dimethylsulfoxide (DMSO), ethyl acetate, chloroform, *N,N*-dimethylformamide (DMF), pyridine (p.a. grade, Baker) and tetrahydrofuran (THF, Baker, HPLC grade) were stored over molecular sieves (4 Å). Toluene was boiled under reflux with P₂O₅ for 3 h, distilled and stored over molecular sieves (4 Å). Anhydrous diethyl ether was freshly distilled from LiAlH₄ prior to use. Sulfuric acid, acetic acid, acetic anhydride (p.a. grade, Baker), ethanol (96%, technical grade) and acetone (Acros, p.a.) were used as received. Vinylmagnesium bromide (1 M in THF, Aldrich), allyl alcohol (Aldrich), platinum(IV) oxide (Acros), allylmagnesium bromide (1 M in Et₂O, Aldrich), 3-buten-1-ol (Aldrich), chlorotris(triphenylphosphine)rhodium(I) ((PPh₃)₃Rh(I)Cl, Aldrich), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, Aldrich), allylmagnesium chloride (2 M in THF, Aldrich), allyl bromide (Aldrich), and sodium hydride (60% dispersion in mineral oil, Acros) were used as received. Montmorillonite K-10 clay (Aldrich) was dried (110 °C, 1 mm Hg, 10 h) before use. Reactions were executed at ambient temperature unless stated otherwise. Drying of organic layers after work-up was effected by addition of MgSO₄. TLC analysis was conducted on DC-Fertigfolien (Schleicher & Schuell, F1500, LS254) or HPTLC aluminum sheets (Merck, silica gel 60, F254) with detection by UV-absorption (254 nm) and charring with 20% H₂SO₄ in ethanol. Column chromatography was performed either on Baker silica gel (0.063–0.200 mm) or Merck silica gel 60 (0.040–0.063 mm). Solvents used for column chromatography were of technical grade and distilled before use. ¹H- and ¹³C-spectra were recorded on a Jeol JNM-FX-200 (200 MHz and 50.1 MHz, respectively) or a Bruker DPX-300 (300 MHz and 75.1 MHz, respectively). NMR shifts are reported in ppm (δ) relative to tetramethylsilane. Mass spectrometry was performed on a PE/SCIEX API 165 equipped with an electrospray interface. Optical rotation values were measured at 20 °C on a Propol Automatic Polarimeter at 589 nm and are given in unit of 10⁻¹ deg cm² g⁻¹.

The atom numbering used for the bi- and tricyclic products is given in Fig. 1.




Fig. 1 The atom numbering used for the bi- and tricyclic products.

General procedure for the Grignard reactions

A solution of the lactone in anhydrous Et₂O (5 mL mmol⁻¹) was cooled to -78 °C under a nitrogen atmosphere. The Grignard reagent (1.0 M solution, 1.2 equiv.) was added dropwise and the mixture was stirred at -78 °C until TLC analysis (33% EtOAc–light petroleum ether) revealed completion of the reaction. The reaction was quenched by addition of sat. NH₄Cl and extracted with Et₂O. The organic layer was washed with sat. NH₄Cl, dried and concentrated. Silica gel chromatography (10 to 30% EtOAc–light petroleum ether) yielded the ketose.

General procedure for the K-10-mediated condensation reactions

To a flask containing Montmorillonite K-10 clay and powdered molecular sieves 4 Å (both flame-dried under vacuum, 200 mass% each), was added a mixture of the ketose and the acceptor (6 equiv.) in anhydrous CH₂Cl₂ (10 mL mmol⁻¹) under an argon atmosphere. The resulting suspension was stirred vigorously until TLC analysis (25% EtOAc–light petroleum ether) revealed completion of the reaction. A mixture of methanol–pyridine (10 mL mmol⁻¹, 1 : 1) was added and stirring was continued for 10 min. The suspension was filtered over Hyflo® and concentrated. Silica gel chromatography (5 to 20% EtOAc–light petroleum ether) of the residue yielded the glycosidation product.

General procedures for ring-closing metathesis

Method A: A 0.08 M solution of the diene in anhydrous toluene was purged for 15 min with argon. Grubbs' catalyst **6** (0.06 equiv.) was added and the mixture was purged with argon for an additional 15 min, after which the solution was heated to 60 °C. Stirring was continued under an argon atmosphere until TLC analysis (20% EtOAc–light petroleum ether) revealed complete disappearance of the starting material. The mixture was allowed to cool to room temperature and was concentrated. The residue was subjected to silica gel chromatography (5 to 20% EtOAc–light petroleum ether) to give the product.

Method B: A 0.08 M solution of the diene in anhydrous dichloromethane was purged for 15 min with argon. Grubbs' catalyst **6** (0.06 equiv.) was added and the mixture was purged with argon for an additional 15 min. Stirring was continued under an argon atmosphere until TLC analysis (20% EtOAc–light petroleum ether) revealed complete disappearance of the starting material. The mixture was concentrated, and purified by silica gel chromatography (5 to 20% EtOAc–light petroleum ether) to give the product.

4,5,6,8-Tetra-*O*-benzyl-1,2-dideoxy- α -D-glucopyranose (2). Prepared from **1** by Grignard addition, according to the general procedure. Colourless syrup (3.82 g, 6.87 mmol, 91%); $[\alpha]_D +46.5$ (*c* 1 in CHCl₃); δ_H (200 MHz; CDCl₃; Me₄Si) 7.14–7.28 (m, 20H, CH_{arom}), 5.99 (dd, 1H, *J* 11.0 and 17.5 Hz, H-2), 5.26 and 5.60 (2d, 2H, *J* 10.2 and 16.8 Hz, 2 × H-1), 4.54, 4.63, 4.79 and 4.88 (4d, 8H, CH₂ Bn), 4.05–4.10 (m, 1H, H-7), 4.01 (br t, 1H, *J* 9.5 Hz, H-5), 3.65–3.78 (m, 2H, H-6,8), 3.46 (dd, 1H, *J* 3.7 and 7.3 Hz, H-8), 3.42 (br d, 1H, *J* 9.5 Hz, H-4), 3.20 (br s, 1H, OH); δ_C (50 MHz; CDCl₃; Me₄Si) 138.6 (C-2), 137.7, 138.1 and 138.6 (C_q Bn), 127.4–128.2 (CH_{arom}), 117.0 (C-1), 96.4 (C-3), 71.4, 78.0, 82.6 and 83.2 (C-4,5,6,7), 73.1, 74.8, 75.5 and 76.4 (CH₂ Bn), 68.6

(C-8); MS (ESI): calc. for C₃₃H₃₈O₆ 566.3, found *m/z* 589.3 (M + Na⁺).

5,6,7,9-Tetra-*O*-benzyl-1,2,3-trideoxy-D-glucopyranose (3). Prepared from **1** by Grignard addition, according to the general procedure. Colourless syrup (3.13 g, 5.40 mmol, 32 %, $\alpha/\beta = 4 : 1$); δ_H (200 MHz; CDCl₃; Me₄Si) 7.29–7.43 (m, 20H, CH_{arom}), 5.99–6.03 (m, 1H, H-2), 5.30 (dd, 2H, 2x H-1), 4.68, 4.71, 4.81, 4.97 and 5.05 (5d, 8H, CH₂ Bn), 4.18 (br t, 1H, *J* 9.5 Hz, H-6), 4.10–4.17 (m, 1H, H-8), 3.66–3.89 (m, 2H, 2 × H-9), 3.78 (br t, 1H, *J* 10.2 Hz, H-7), 3.57 (br d, 1H, *J* 9.5 Hz, H-5), 2.58 (d, 2H, *J* 6.6 Hz, H-3); δ_C (50 MHz; CDCl₃; Me₄Si) 137.8, 138.0 and 138.4 (C_q Bn), 132.1 (C-2), 126.7–128.2 (CH_{arom}), 119.8 (C-1), 97.6 (C-4), 71.3, 78.3, 81.2 and 83.5 (C-5,6,7,8), 73.1, 74.7, 75.1 and 75.4 (CH₂ Bn), 68.5 (C-9), 42.6 (C-3); MS (ESI): calc. for C₃₇H₄₀O₆ 580.3, found *m/z* 603.4 (M + Na⁺).

Allyl (4,5,6,8-tetra-*O*-benzyl-1,2-dideoxy)- α -D-glucopyranose (4). Prepared from **2** by K-10-mediated glycosidation according to the general procedure. Colourless syrup (238 mg, 0.39 mmol, 74%); δ_H (200 MHz; CDCl₃; Me₄Si) 7.34–7.43 (m, 20H, CH_{arom}), 5.99–6.12 (m, 2H, *J* 11.0, 17.5 Hz, H-2 and CH All), 5.69 (dd, 1H, *J* 1.5, 17.5 Hz, H-1), 5.40 (dd, 1H, *J* 1.5, 11.0 Hz, H-1), 5.35 (d, 1H, *J* 6.6 Hz, CH₂ All), 5.23 (d, 1H, *J* 10.2 Hz, CH₂ All), 4.68, 4.73, 4.78, 4.99, and 5.00 (5d, 8H, CH₂ Bn), 4.29 (br t, 1H, *J* 8.8 Hz, H-5), 4.06 (t, 2H, *J* 5.9 Hz, CH₂ All), 3.81–3.94 (m, 4H, H-6,7 and 2 × H-8), 3.50 (d, 1H, *J* 9.5 Hz, H-4); δ_C (50 MHz; CDCl₃; Me₄Si) 138.3, 138.4 and 138.8 (C_q Bn), 135.4 (C-2), 134.8 (CH All), 127.6–128.4 (CH_{arom}), 118.7 (C-1), 116.6 (CH₂ All), 99.8 (C-3), 71.9, 78.5, 83.0 and 84.3 (C-4,5,6,7), 73.3, 75.0, 75.6 and 75.8 (CH₂ Bn), 68.8 (C-8), 63.0 (CH₂ All); MS (ESI): calc. for C₃₉H₄₂O₆ 606.3, found *m/z* 629.5 (M + Na⁺).

Allyl (5,6,7,9-tetra-*O*-benzyl-1,2,3-trideoxy)- α -D-glucopyranose (5). Prepared from **3** by K-10-mediated glycosidation according to the general procedure. Colourless syrup (228 mg, 0.37 mmol, 69%); δ_H (200 MHz; CDCl₃; Me₄Si) 7.21–7.30 (m, 20H, CH_{arom}), 5.81–6.02 (m, 2H, H-2 and CH allyl), 5.28 (d, 1H, *J* 17.5 Hz, H-1), 5.05–5.14 (m, 3H, H-1 and CH₂ allyl), 4.52, 4.57, 4.63, 4.71, 4.84 and 4.93 (6d, 8H, CH₂ Bn), 4.14 (br t, 1H, *J* 9.5 Hz, H-6), 4.07 (d, 2H, *J* 5.8, CH₂ All), 3.61–3.77 (m, 4H, H-7,8 and 2 × H-9), 3.53 (br d, 1H, *J* 9.5 Hz, H-4), 2.63 (d, 2H, *J* 7.3 Hz, 2 × H-3); δ_C (50 MHz; CDCl₃; Me₄Si) 138.3 and 138.7 (C_q Bn), 135.0 (C-2), 133.6 (CH allyl), 127.5–128.4 (CH_{arom}), 118.1 (CH₂ allyl), 116.4 (C-1), 101.9 (C-4), 72.0, 78.8, 81.2 and 83.6 (C-5,6,7,8), 73.3, 74.9, 75.1 and 75.5 (CH₂ Bn), 68.9 (C-9), 61.7 (CH₂allyl), 42.6 (C-3); MS (ESI): calc. for C₄₀H₄₄O₆ 620.3, found *m/z* 643.4 (M + Na⁺).

(5*S*,7*R*,8*R*,9*S*,10*R*)-8,9,10-Tris-benzyloxy-7-benzyloxy-methyl-1,6-dioxaspiro[4.5]dec-3-ene (7). Obtained by RCM of **4**, *via* method A of the general procedure, as a greenish syrup (216 mg, 0.37 mmol, 95%); $[\alpha]_D +67.2$ (*c* 1 in CH₂Cl₂); δ_H (300 MHz; CDCl₃; Me₄Si) 7.11–7.24 (m, 20H, CH_{arom}), 6.19 (d, 1H, *J* 5.8 Hz, H-4), 5.62 (m, 1H, H-3), 4.44, 4.54, 4.59, 4.71, 4.74, 4.84, 4.85 and 4.93 (8d, 8H, CH₂ Bn), 4.04 (br t, 1H, *J* 9.5 Hz, H-9), 3.98 (dd, 1H, *J* 6.6 Hz, H-11), 3.71–3.80 (m, 3H, H-7,8,11), 3.64 (d, 1H, *J* 9.5 Hz, H-10), 2.25 (d, 2H, *J* 11.7 Hz, 2 × H-2); δ_C (50 MHz; CDCl₃; Me₄Si) 138.0 (C_q Bn), 138.3 and 138.7 (C_q Bn), 132.2 (C-4), 127.2–128.2 (C-3 and CH_{arom}), 112.1 (C-5), 72.3, 77.8, 81.3 and 83.6 (C-7,8,9,10), 73.3 and 74.7 (CH₂ Bn), 72.2 (C-2), 68.5 (CH₂OBN); MS (ESI): calc. for C₃₇H₃₈O₆ 578.3, found *m/z* 601.3 (M + Na⁺).

(2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-Tris-benzyloxy-2-benzyloxymethyl-1,7-dioxaspiro[5.5]undec-9-ene (8). Obtained by RCM of **5** *via* method A of the general procedure as a greenish syrup (634 mg, 1.1 mmol, 90%); $[\alpha]_D +34.2$ (*c* 0.57 in CH₂Cl₂); δ_H (300 MHz;

CDCl₃; Me₄Si) 7.25–7.40 (m, 20H, CH_{arom}), 5.77 (m, 2H, H-9,10), 4.60, 4.66, 4.71, 4.78, 4.96 and 5.07 (6d, 8H, CH₂ Bn), 4.30 (br t, 1H, *J* 8.8 Hz, H-4), 4.22 (br s, 2H, 2 × H-8), 3.78–3.89 (m, 4H, H-2,3 and CH₂OBn), 3.47 (d, 1H, *J* 9.5 Hz, H-5), 2.63 (d, 1H, *J* 17.5 Hz, H-11), 1.88 (d, 1H, *J* 16.8 Hz, H-11); δ_C (50 MHz; CDCl₃; Me₄Si) 137.7, 138.0 and 138.5 (C_q Bn), 127.5–128.5 (CH_{arom}), 123.6 (C-9), 121.2 (C-10), 97.2 (C-6), 71.6, 78.5, 82.0 and 83.3 (C-2,3,4,5), 73.2, 74.8, 75.5, and 75.7 (CH₂Bn), 68.5 (CH₂OBn), 59.8 (C-8), 29.9 (C-11); MS (ESI): calc. for C₃₈H₄₀O₆ 592.3, found *m/z* 615.3 (M + Na)⁺.

(5S,7R,8R,9S,10R)-8,9,10-Tris-benzyloxy-7-benzyloxy-methyl-1,6-dioxaspiro[4.5]decane (9). Compound **7** (47 mg, 81 μmol) was dissolved in anhydrous EtOAc (3 mL) and platinum(IV) oxide (10 mg) was added. The mixture was degassed three times after which hydrogen gas was introduced. The mixture was stirred for 5 h when TLC analysis (25% EtOAc–light petroleum ether) revealed a completed conversion. The mixture was purged with nitrogen gas, filtered over Hyflo[®] and concentrated. Silica gel chromatography (10% EtOAc–light petroleum ether) of the residue yielded **9** as a colourless syrup (40 mg, 69 μmol, 85%); δ_H (200 MHz; CDCl₃; Me₄Si) 7.33–7.20 (m, 20H, CH_{arom}), 4.54, 4.58, 4.71, 4.87, 4.93 and 4.99 (6d, 8H, CH₂ Bn), 4.07 (br t, 1H, *J* 9.5 Hz, H-9), 4.04 (m, 1H, CH₂OBn), 3.84–3.91 (m, 2H, H-2 and CH₂OBn), 3.67–3.79 (m, 3H, H-2,7,8), 3.58 (d, 1H, *J* 9.5 Hz, H-10), 1.86–1.97 (m, 4H, 2 × H-3 and 2 × H-4); δ_C (50 MHz; CDCl₃; Me₄Si) 138.0, 138.1, 138.3 and 138.7 (C_q Bn), 127.5–128.4 (CH_{arom}), 107.4 (C-5), 71.2, 78.5, 80.0 and 84.5 (C-7,8,9,10), 75.5, 75.6 and 76.4 (CH₂ Bn), 68.7 (CH₂OBn), 68.1 (C-8), 33.4 (C-4), 24.0 (C-3); MS (ESI): calc. for C₃₇H₄₀O₆ 580.3, found *m/z* 603.4 (M + Na)⁺.

3-Buten-1-yl (4,5,6,8-tetra-O-benzyl-1,2-dideoxy)-α-D-glucopyranose (10). Prepared from **2** by K-10-mediated glycosidation according to the general procedure. Colourless syrup (223 mg, 0.36 mmol, 68%); δ_H (200 MHz; CDCl₃; Me₄Si) 7.22–7.30 (m, 20H, CH_{arom}), 5.92 (dd, 1H, *J* 11.0 and 17.5 Hz, H-2), 5.75 (dd, 1H, *J* 7.3 and 17.5 Hz, CH Bu), 5.56 (dd, 1H, *J* 1.5 and 17.5 Hz, H-1), 5.26 (dd, 1H, *J* 2.2 and 11.0 Hz, H-1), 5.06 (d, 1H, *J* 15.3 Hz, CH₂ Bu), 4.97 (d, 1H, *J* 5.1 Hz, CH₂ Bu), 4.54, 4.60, 4.64, 4.85, and 4.87 (5d, 8H, CH₂ Bn), 4.15 (br t, 1H, *J* 8.8 Hz, H-5), 3.71 (br t, 1H, *J* 8.8 Hz, H-6), 3.62–3.81 (m, 2H, CH₂ Bu), 3.42–3.52 (m, 3H, H-7 and 2 × H-8), 3.35 (d, 1H, *J* 9.5 Hz, H-4), 2.36 (dd, 2H, *J* 7.3 and 13.9 Hz, CH₂ Bu); δ_C (50 MHz; CDCl₃; Me₄Si) 138.3, 138.5 and 138.9 (C_q Bn), 135.6 (C-2), 135.1 (CH Bu), 127.6–128.4 (CH_{arom}), 118.5 (C-1), 116.5 (CH₂ Bu), 99.5 (C-3), 71.8, 78.6, 83.0 and 84.5 (C-4,5,6,7), 73.4, 75.0, 75.5 and 75.7 (CH₂ Bn), 68.9 (C-8), 61.2 (CH₂ Bu), 34.2 (CH₂ Bu); MS (ESI): calc. for C₄₀H₄₄O₆ 620.3, found *m/z* 643.4 (M + Na)⁺.

(2R,3R,4S,5R,6S)-3,4,5-Tris-benzyloxy-2-benzyloxymethyl-1,7-dioxaspiro[5.5]undec-10-ene (11). Obtained from **10** by RCM according to the general procedure (method A) as a colourless syrup (188 mg, 0.32 mmol, 88%); [α]_D +40.4 (*c* 1 in CH₂Cl₂); δ_H (300 MHz; CDCl₃; Me₄Si) 7.06–7.68 (m, 20H, CH_{arom}), 6.10 (dd, 1H, *J* 4.7 and 9.9 Hz, H-10), 5.53 (dd, 1H, *J* 1.6 and 10.1 Hz, H-11), 4.51, 4.62, 4.69, 4.78, 4.83 and 4.93 (6d, 8H, CH₂ Bn), 4.06 (br t, 1H, *J* 9.3 Hz, H-4), 3.88 (ddd, 1H, *J* 1.9, 3.6 and 10.3 Hz, H-2), 3.86 (m, 1H, H-8), 3.75 (dd, 1H, *J* 3.8 and 10.8 Hz, CH₂OBn), 3.65 (br t, 1H, *J* 9.9 and 9.0 Hz, H-3), 3.64 (dd, 1H, *J* 1.6 and 10.6 Hz, CH₂OBn), 3.48 (br d, 1H, *J* 9.6 Hz, H-5), 2.43 (m, 1H, H-9), 1.89 (m, 1H, H-9); δ_C (50 MHz; CDCl₃; Me₄Si) 138.0, 138.2, 138, 3 and 138.8 (C_q Bn), 130.3 (C-10), 127.6–128.6 (C-11 and CH_{arom}), 95.6 (C-6), 71.0, 78.2, 82.9 and 83.2 (C-2,3,4,5), 73.4, 74.9, 75.3 and 75.7 (CH₂Bn), 68.8 (CH₂OBn), 58.1 (C-8), 24.2 (C-9); MS (ESI): calc. for C₃₈H₄₀O₆ 592.3, found *m/z* 615.3 (M + Na)⁺, 631.4 (M + K)⁺.

3-Buten-1-yl (5,6,7,9-tetra-O-benzyl-1,2,3-trideoxy)-α-D-glucopyranose (12). Prepared from **3** by K-10-mediated glycosidation according to the general procedure. Colourless syrup (181 mg, 0.29 mmol, 69%); δ_H (200 MHz; CDCl₃; Me₄Si) 7.22–7.31 (m, 20H, CH_{arom}), 5.80 (m, 2H, H-2 and CH Bu), 5.01–5.12 (m, 4H, 2 × H-1 and CH₂ Bu), 4.53, 4.58, 4.65, 4.70, 4.85 and 4.91 (6d, 8H, CH₂ Bn), 4.12 (br t, 1H, *J* 9.5 Hz, H-6), 3.48–3.78 (m, 7H, H-5,7,8 and 2 × H-9 and CH₂ Bu), 2.64 (m, 2H, 2 × H-3), 2.39 (m, 2H, CH₂ Bu); δ_C (50 MHz; CDCl₃; Me₄Si) 138.8 (C_q Bn), 135.0 (C-2), 133.7 (CH Bu), 127.5–128.4 (CH_{arom}), 118.0 (CH₂ Bu), 116.7 (C-1), 101.5 (C-4), 72.0, 78.8, 81.3 and 83.4 (C-5,6,7,8), 73.2, 74.8, 75.0 and 75.4 (CH₂ Bn), 68.9 (C-9), 60.0 (CH₂ Bu), 38.0 (C-3), 34.4 (CH₂ Bu); MS (ESI): calc. for C₄₁H₄₆O₆ 634.3, found *m/z* 657.5 (M + Na)⁺.

4-Penten-1-yl (5,6,7,9-tetra-O-benzyl-1,2,3-trideoxy)-α-D-glucopyranose (13). Prepared from **3** by K-10-mediated glycosidation according to the general procedure. Colourless syrup (638 mg, 0.98 mmol, 80%); δ_H (200 MHz; CDCl₃; Me₄Si) 7.47–7.52 (m, 20H, CH_{arom}), 5.94–6.11 (m, 2H, H-2 and CH Pent), 4.76, 4.85, 4.86, 4.95, 5.11, 5.13 and 5.15 (7d, 8H, CH₂ Bn), 4.38 (br t, 1H, *J* 9.5 Hz, H-6), 3.71–4.01 (m, 7H, H-5,7,8 and 2 × H-9 and CH₂ Pent), 2.86 (m, 2H, CH₂ Pent), 2.35 (m, 2H, 2 × H-3), 1.94–2.00 (m, 2H, CH₂ pent); δ_C (50 MHz; CDCl₃; Me₄Si) 138.4, 138.7 and 138.9 (C_q Bn), 138.3 (CH Pent), 134.0 (C-2), 127.6–128.5 (CH_{arom}), 118.0 (C-1), 115.0 (CH₂ Pent), 101.6 (C-4), 72.1, 78.9, 81.4 and 83.6 (C-5,6,7,8), 73.4, 74.8, 75.1 and 75.5 (CH₂ Bn), 69.0 (C-9), 59.8 (CH₂ Pent), 38.1 (C-3), 30.6 (CH₂ Pent), 29.1 (CH₂ Pent); MS (ESI): calc. for C₄₂H₄₈O₆ 648.3, found *m/z* 671.3 (M + Na)⁺.

(2R,3R,4S,5R,6S)-3,4,5-Tris-benzyloxy-2-benzyloxymethyl-1,7-dioxaspiro[5.6]dodec-10-ene (14). Obtained from **12** by RCM according to the general procedure (method A) as a colourless syrup (128 mg, 0.21 mmol, 95%); [α]_D +47.4 (*c* 1 in CH₂Cl₂); δ_H (200 MHz; CDCl₃; Me₄Si) 7.19–7.32 (m, 20H, CH_{arom}), 5.69 (m, 1H, H-11), 5.52 (m, 1H, H-10), 4.52, 4.55, 4.61, 4.70, 4.86 and 4.92 (6d, 8H, CH₂ Bn), 4.07 (br t, 1H, *J* 9.5 Hz, H-4), 3.69–3.90 (m, 5H, H-2 and 2 × H-8 and CH₂OBn), 3.63 (br t, 1H, *J* 9.5 Hz, H-3), 3.33 (d, 1H, *J* 9.5 Hz, H-5), 2.75 (d, 2H, *J* 16.1 Hz, H-12), 2.19–2.42 (m, 3H, H-12 and 2 × H-9); δ_C (50 MHz; CDCl₃; Me₄Si) 138.7 (C_q Bn), 129.7 (C-11), 127.6–128.7 (CH_{arom}), 124.7 (C-10), 101.4 (C-6), 71.5, 78.7, 83.6 and 84.7 (C-2,3,4,5), 73.3, 74.9, and 75.6 (CH₂ Bn), 68.7 (CH₂OBn), 61.8 (C-8), 36.3 (C-9), 31.3 (C-12); MS (ESI): calc. for C₃₉H₄₂O₆ 606.3, found *m/z* 629.4 (M + Na)⁺.

(2R,3R,4S,5R,6S)-3,4,5-Tris-benzyloxy-2-benzyloxymethyl-1,7-dioxaspiro[5.7]tridec-11-ene (15). Obtained from **13** by RCM according to the general procedure (method A) as a greenish syrup (319 mg, 0.51 mmol, 90%); [α]_D +15.8 (*c* 1 in CHCl₃); δ_H (300 MHz; CDCl₃; Me₄Si) 7.30–7.41 (m, 20H, CH_{arom}), 5.89 (m, 2H, H-11,12), 4.68, 4.72, 4.78, 4.86, 5.00, 5.05 and 5.09 (7d, 8H, CH₂ Bn), 4.19 (br t, 1H, *J* 8.8 Hz, H-4), 4.05 (d, 1H, *J* 11.7 Hz, CH₂OBn), 3.59–3.84 (m, 5H, H-2,3 and 2 × H-8 and CH₂OBn), 3.57 (d, 1H, *J* 9.5 Hz, H-5), 2.79 (dd, 1H, *J* 5.8 and 13.9 Hz, H-13), 2.04–2.45 (m, 4H, 2 × H-9 and 2 × H-10); δ_C (50 MHz; CDCl₃; Me₄Si) 137.8, 137.9, 138.1 and 138.6 (C_q Bn), 131.2 (C-12), 127.3–128.2 (CH_{arom}), 126.3 (C-11), 102.0 (C-6), 72.0, 78.4, 83.5 and 84.7 (C-2,3,4,5), 73.1, 74.8, and 75.4 (CH₂ Bn), 68.4 (CH₂OBn), 59.2 (C-8), 35.0 (C-13), 30.7 (C-10), 23.7 (C-9); MS (ESI): calc. for C₄₀H₄₄O₆ 620.3, found *m/z* 643.4 (M + Na)⁺.

5,6,7-Tri-O-benzyl-1,2,3-trideoxy-α-L-fuco-non-1-eno-4-ulopyranose (16). Prepared from 5,6,7-tri-O-benzyl-L-fuco-1,5-lactone¹⁶ by Grignard addition, according to the general procedure. Colourless syrup (1.42 g, 2.99 mmol, 87%); δ_H (200

MHz; CDCl₃; Me₄Si) 7.22–7.39 (m, 15H, CH_{arom}), 5.82–5.94 (m, 1H, H-2), 5.16 (dd, 2H, *J* 4.4 and 5.8 Hz, 2 × H-1), 4.73 (m, 3H, CH₂ Bn), 4.70, 4.98 and 4.99 (3d, each 1H, CH₂ Bn), 3.78–4.05 (m, 3H, H-5,6,8), 3.66 (d, 1H, *J* 1.5 Hz, H-7), 2.75 (s, 1H, OH), 2.35–2.55 (m, 2H, 2 × H-3), 1.14 (d, 3H, *J* 6.6 Hz, CH₃); δ_C (50 MHz; CDCl₃; Me₄Si) 138.4 (C_q Bn), 132.9 (C-1), 127.5–128.9 (CH_{arom}), 119.0 (C-2), 98.0 (C-4), 77.5, 78.0 and 81.4 (C-5,6,7), 72.5, 74.4 and 75.3 (CH₂ Bn), 67.1 (C-8), 43.2 (C-3), 16.9 (CH₃); MS (ESI): calc. for C₃₀H₃₄O₅ 474.2, found *m/z* 497.2 (M + Na)⁺.

Allyl (5,6,7-tri-*O*-benzyl-1,2,3-trideoxy)-α-*L*-fuco-non-1-eno-4-ulopyranose (17). Prepared from **16** by K-10-mediated glycosidation according to the general procedure. Colourless syrup (1.07 g, 2.08 mmol, 70%); δ_H (200 MHz; CDCl₃; Me₄Si) 7.26–7.44 (m, 15H, CH_{arom}), 5.84–6.00 (m, 2H, H-2 and CH allyl), 5.26 and 5.34 (2d, 2H, *J* 1.5 and 16.8 Hz, CH₂ allyl), 5.12 and 5.17 (2d, 2H, *J* 1.5 and 10.2 Hz, 2 × H-1), 4.71, 4.74 and 5.00 (3d, each 1H, CH₂ Bn), 4.78 and 5.04 (m, 3H, CH₂ Bn), 3.99–4.18 (m, 3H, H-5,6,8), 3.80 (dd, 2H, *J* 6.6 and 13.1 Hz, CH₂ allyl), 3.71 (d, 1H, *J* 2.2 Hz, H-7), 2.66 (m, 2H, H-3), 1.20 (d, 3H, *J* 5.8 Hz, CH₃); δ_C (50 MHz; CDCl₃; Me₄Si) 138.9 and 139.2 (C_q Bn), 135.5 (C-1), 134.2 (CH₂ allyl), 127.0–128.8 (CH_{arom}), 117.5 (C-2), 116.2 (CH allyl), 102.1 (C-4), 78.0, 78.2 and 81.2 (C-5,6,7), 72.7, 74.5 and 75.1 (CH₂ Bn), 67.5 (C-8), 61.6 (CH₂ allyl), 39.0 (C-3), 16.9 (CH₃); MS (ESI): calc. for C₃₃H₃₈O₅ 514.3, found *m/z* 537.4 (M + Na)⁺.

(2*S*,3*R*,4*R*,5*S*,6*R*)-3,4,5-Tris-benzyloxy-2-methyl-1,7-dioxaspiro[5.5]undec-9-ene (18). Obtained from **17** by RCM according to the general procedure (method B) as a greenish syrup (0.90 g, 1.85 mmol, 90%); [α]_D –51.4 (*c* 1 in CHCl₃); δ_H (300 MHz; CDCl₃; Me₄Si) 7.30–7.24 (m, 15H, CH_{arom}), 5.66 (s, 2H, H-9,10), 4.71, 4.99 and 5.00 (3d, each 1H, CH₂ Bn), 4.77 (s, 3H, CH₂ Bn), 4.04–4.19 (m, 3H, H-2,4,5), 3.80 (dd, 2H, *J* 10.2 and 15.3 Hz, H-8), 3.69 (d, 1H, *J* 1.5 Hz, H-3), 2.57 (m, 1H, H-11), 1.82 (m, 1H, H-11), 1.16 (d, 3H, *J* 6.6 Hz, CH₃); δ_C (50 MHz; CDCl₃; Me₄Si) 138.2, 138.7 and 138.8 (C_q Bn), 127.6–128.7 (CH_{arom}), 121.7 and 123.8 (C-9,10), 97.6 (C-6), 78.1, 78.5 and 80.9 (C-3,4,5), 72.7, 74.6 and 75.9 (CH₂ Bn), 67.1 (C-2), 60.3 (C-8), 30.4 (C-11), 16.9 (CH₃); MS (ESI): calc. for C₃₁H₃₄O₅ 486.2, found *m/z* 509.3 (M + Na)⁺.

5,6,7-Tri-*O*-benzyl-1,2,3-trideoxy-α-*L*-rhamno-non-1-eno-4-ulopyranose (19). Prepared from 5,6,7-tri-*O*-benzyl-*L*-rhamno-1,5-lactone¹⁸ by Grignard addition, according to the general procedure. Colourless syrup (1.49 g, 3.14 mmol, 90%); δ_H (200 MHz; CDCl₃; Me₄Si) 7.51–7.59 (m, CH_{arom}), 6.00–6.12 (m, 1H, H-2), 4.88–5.45 (m, 8H, 2 × H-1 and CH₂ Bn), 4.38 (d, 1H, *J* 9.5 Hz, H-6), 3.89–4.20 (m, 3H, H-5,7,8), 3.05 (s, 1H, OH), 2.93 (dd, 1H, *J* 5.1 and 13.9 Hz, H-3), 2.54 (dd, 1H, *J* 9.5 and 13.2 Hz, H-3), 1.56 (d, 3H, *J* 5.8 Hz, CH₃); δ_C (50 MHz; CDCl₃; Me₄Si) 138.8, 138.9 (C_q Bn), 132.7 (C-1), 127.7–128.7 (CH_{arom}), 120.6 (C-2), 98.0 (C-4), 68.8, 77.7, 80.7 and 81.9 (C-5,6,7,8), 72.7, 74.8 and 75.3 (CH₂ Bn), 42.8 (C-3), 18.3 (CH₃); MS (ESI): calc. for C₃₀H₃₄O₅ 474.2, found *m/z* 497.3 (M + Na)⁺.

Allyl (5,6,7-tri-*O*-benzyl-1,2,3-trideoxy)-α-*L*-rhamno-non-1-eno-4-ulopyranose (20). Prepared from **19** by K-10-mediated glycosidation according to the general procedure. Colourless syrup (1.43 g, 2.78 mmol, 89%); δ_H (200 MHz; CDCl₃; Me₄Si) 7.50–7.65 (m, 15H, CH_{arom}), 5.83–6.20 (m, 2H, H-2 and CH allyl), 5.49 (d, 1H, *J* 16.8 Hz, H-1), 5.17 (d, 1H, CH₂ Bn), 4.90–5.39 (m, 7H, H-1, CH₂ allyl and Bn), 4.79 (d, 1H, CH₂ Bn), 4.39 (d, 1H, *J* 8.8 Hz, H-6), 4.20 (br s, 2H, 2 × H-10), 4.015 (d, 1H, *J* 2.9 Hz, H-5), 3.83–4.00 (m, 2H, H-7,8), 3.07 (dd, 1H, *J* 7.3 and 15.3 Hz, H-3), 2.76 (dd, 1H, *J* 5.8 and 15.3 Hz, H-3), 1.57 (d, 3H, *J* 5.1 Hz, CH₃); δ_C (50 MHz; CDCl₃; Me₄Si) 138.7, 138.8 and 139.0 (C_q Bn), 134.4 (CH₂ allyl), 132.7 (C-1), 127.6–128.5

(CH_{arom}), 118.6 (C-2), 116.3 (CH allyl), 102.4 (C-4), 69.4, 76.4, 80.4 and 82.0 (C-5,6,7,8), 72.6, 74.9, 75.1 and 75.4 (CH₂ Bn), 61.0 (CH₂ allyl), 36.4 (C-3), 18.2 (CH₃); MS (ESI): calc. for C₃₃H₃₈O₅ 514.3, found *m/z* 537.4 (M + Na)⁺.

(2*S*,3*S*,4*R*,5*R*,6*R*)-3,4,5-Tris-benzyloxy-2-methyl-1,7-dioxaspiro[5.5]undec-9-ene (21). Obtained from **20** by RCM according to the general procedure (method B) as a greenish syrup (1.35 g, 2.78 mmol, 85%); [α]_D –27.2 (*c* 1 in CHCl₃); δ_H (300 MHz; CDCl₃; Me₄Si) 7.31–7.43 (m, 15H, CH_{arom}), 5.68 (s, 2H, H-9,10), 4.66, 4.68, 4.80, 4.94 and 5.02 (5d, 6H, CH₂ Bn), 4.00–4.12 (m, 3H, H-2,3,4), 3.79 (d, 1H, *J* 2.2 Hz, H-5), 3.66 (dd, 2H, *J* 7.3 and 16.1 Hz, H-8), 2.25 (m, 1H, H-11), 2.01 (m, 1H, H-11), 1.35 (d, 3H, *J* 5.0 Hz, CH₃); δ_C (50 MHz; CDCl₃; Me₄Si) 137.3, 137.6 and 137.8 (C_q Bn), 126.9–130.0 (CH_{arom}), 121.6 and 123.9 (C-9,10), 97.4 (C-6), 78.7, 80.3 and 81.5 (C-3,4,5), 72.6, 74.9 and 75.2 (CH₂ Bn), 68.9 (C-2), 59.6 (C-8), 32.2 (C-11), 17.9 (CH₃); MS (ESI): calc. for C₃₁H₃₄O₅ 486.2, found *m/z* 509.3 (M + Na)⁺.

1,2-Dideoxy-4,5;7,8-di-*O*-isopropylidene-α-*D*-manno-oct-1-eno-3-ulofuranose (22). Prepared from 2,3;5,6-di-*O*-isopropylidene-*D*-manno-1,4-lactone¹⁹ by Grignard addition, according to the general procedure. Colourless syrup (1.34 g, 4.7 mmol, 45%); δ_H (200 MHz; CDCl₃; Me₄Si) 5.89 (dd, 1H, *J* 10.9 and 17.5 Hz, H-2), 5.41 (dd, 1H, *J* 1.5 and 17.5 Hz, H-1), 5.20 (dd, 1H, *J* 1.5 and 10.9 Hz, H-1), 4.72 (dd, 1H, *J* 2.9 and 5.1 Hz, H-5), 4.34 (d, 1H, *J* 5.8 Hz, H-4), 4.25 (m, 1H, H-7), 4.02 (dd, 1H, *J* 3.6 and 7.3 Hz, H-8), 3.86–3.97 (m, 3H, H-6,8 and OH), 1.17, 1.23, 1.31 and 1.32 (4s, each 3H, CH₃); δ_C (50 MHz; CDCl₃; Me₄Si) 136.2 (C-2), 117.0 (C-1), 112.4 (C-3), 104.1 and 108.7 (C_q), 73.1, 78.9, 80.1 and 86.5 (C-4,5,6,7), 66.2 (C-8), 24.1, 25.0, 25.6 and 26.5 (CH₃); MS (ESI): calc. for C₁₄H₂₂O₆ 286.1, found *m/z* 309.1 (M + Na)⁺.

Allyl (1,2-dideoxy-4,5;7,8-di-*O*-isopropylidene)-α-*D*-manno-oct-1-eno-3-ulofuranose (23). Prepared from **22** by K-10-mediated glycosidation according to the general procedure. Colourless syrup (0.73 g, 2.24 mmol, 66%); δ_H (200 MHz; CDCl₃; Me₄Si) 5.52–5.72 (m, 2H, H-2 and CH allyl), 5.31 (dd, 1H, *J* 2.2 and 21.9 Hz, H-1), 5.16 (dd, 1H, *J* 2.2 and 16.1 Hz, H-1), 4.98 (br t, 2H, CH₂ allyl), 4.67 (dd, 1H, *J* 3.6 and 5.8 Hz, H-5), 4.37 (d, 1H, *J* 5.8 Hz, H-4), 4.25 (dd, 1H, *J* 6.6 and 13.1 Hz, H-8), 3.82–3.99 (m, 3H, H-6,7,8), 3.64 (m, 2H, CH₂ allyl), 1.14, 1.21, 1.26 and 1.28 (4s, each 3H, CH₃); δ_C (50 MHz; CDCl₃; Me₄Si) 134.4 (CH allyl), 132.6 (C-2), 118.8 (C-1), 115.9 (CH₂ allyl), 112.3 (C-3), 107.8 and 108.7 (C_q), 72.9, 79.1, 79.9 and 86.3 (C-4,5,6,7), 66.6 (C-8), 62.4 (CH₂ allyl), 24.3, 25.0, 25.6 and 26.5 (CH₃); MS (ESI): calc. for C₁₇H₂₆O₆ 326.2, found *m/z* 349.0 (M + Na)⁺.

(2*R*,3*S*,4*S*,5*S*)-3,4-Dihydroxy-3,4-*O*-isopropylidene-2-((*R*)-1,2-dihydroxy-1,2-*O*-isopropylidene)ethyl)-1,6-dioxaspiro[4.4]non-8-ene (24). Obtained from **23** by RCM according to the general procedure (method B) as a greenish syrup (0.63 g, 2.11 mmol, 95%); [α]_D –10.4 (*c* 1 in CHCl₃); δ_H (600 MHz; CDCl₃; Me₄Si) 6.17 (d, 1H, *J* 6.0 Hz, H-9), 5.73 (m, 1H, H-8), 4.76 (dd, 1H, *J* 4.1 and 5.4 Hz, H-3), 4.58 (d, 1H, *J* 14.0 Hz, H-7), 4.48 (d, 1H, *J* 13.9 Hz, H-7), 4.46 (d, 1H, *J* 5.9 Hz, H-4), 4.23 (m, 1H, CH Et), 3.95 (t, 1H, *J* 8.7 Hz, CH₂ Et), 3.86–3.90 (m, 2H, H-2 and CH₂ Et), 1.21, 1.24, 1.32 and 1.38 (4s, each 3H, CH₃); δ_C (50 MHz; CDCl₃; Me₄Si) 132.6 (C-9), 124.5 (C-8), 119.2 (C-5), 108.8 and 112.4 (C_q), 72.9, 79.9 and 85.7 (C-2,3,4 and CH Et), 74.6 (C-7), 66.8 (CH₂ Et), 24.3, 25.0, 25.7 and 26.7 (CH₃); MS (ESI): calc. for C₁₅H₂₂O₆ 298.1, found *m/z* 321.0 (M + Na)⁺, 337.2 (M + K)⁺.

1,2,3-Trideoxy-5,6,8,9-di-*O*-isopropylidene-α-*D*-manno-non-1-eno-4-ulofuranose (25). Prepared from 2,3;5,6-di-*O*-isopropylidene-*D*-manno-1,4-lactone¹⁹ by Grignard addition, according

to the general procedure. Colourless syrup (1.65 g, 5.50 mmol, 95%); δ_{H} (200 MHz; CDCl_3 ; Me_4Si) 5.75–5.96 (m, 1H, H-2), 5.23 (dd, 2H, J 10.2 and 17.5 Hz, $2 \times$ H-1), 4.84 (dd, 1H, J 3.7 and 4.8 Hz, H-6), 4.49 (d, 1H, J 6.6 Hz, H-5), 4.37 (m, 2H, H-8,9), 3.97–4.20 (m, 3H, H-7,9 and OH), 2.52 (d, 2H, J 6.6 Hz, $2 \times$ H-3), 1.34, 1.38, 1.45 and 1.49 (4s, each 3H, CH_3); δ_{C} (50 MHz; CDCl_3 ; Me_4Si) 123.4 (C-2), 119.0 (C-1), 112.2 (C-4), 105.1 and 108.7 (C_q), 73.0, 78.6, 79.9 and 84.8 (C-5,6,7,8), 66.3 (C-9), 39.6 (C-3), 24.1, 24.9, 25.5 and 26.5 (CH_3); MS (ESI): calc. for $\text{C}_{15}\text{H}_{24}\text{O}_6$ 300.2, found m/z 323.2 ($\text{M} + \text{Na}$) $^+$.

Allyl (1,2,3-trideoxy-5,6;8,9-di-*O*-isopropylidene)- α -D-manno-non-1-eno-4-ulofuranose (26). Prepared from **25** by K-10-mediated glycosidation according to the general procedure. Colourless syrup (0.60 g, 1.76 mmol, 54%); δ_{H} (200 MHz; CDCl_3 ; Me_4Si) 5.64–5.84 (m, 2H, H-2 and CH allyl), 5.19 (m, 1H, H-1), 4.97–5.10 (m, 3H, H-1 and CH_2 allyl), 4.71 (dd, 1H, J 4.0 and 5.8 Hz, H-6), 4.38 (d, 1H, J 5.8 Hz, H-5), 4.24–4.30 (m, 1H, H-9), 3.94–4.03 (dd, 1H, J 6.2 and 8.4 Hz, H-8), 3.79–3.90 (m, 3H, H-9 and CH_2 allyl), 3.72 (dd, 1H, J 3.7 and 7.7 Hz, H-7), 2.51 (d, 2H, J 7.7 Hz, $2 \times$ H-3), 1.23, 1.27, 1.34 and 1.38 (4s, each 3H, CH_3); δ_{C} (50 MHz; CDCl_3 ; Me_4Si) 134.3 (CH allyl), 132.1 (C-2), 117.6 (C-1), 116.1 (CH_2 allyl), 112.2 (C-4), 108.7 and 108.9 (C_q), 72.8, 79.2, 79.8 and 84.6 (C-5,6,7,8), 66.7 (C-9), 61.3 (CH_2 allyl), 34.2 (C-3), 24.3, 25.0, 25.7 and 26.6 (CH_3); MS (ESI): calc. for $\text{C}_{18}\text{H}_{28}\text{O}_6$ 340.2, found m/z 363.2 ($\text{M} + \text{Na}$) $^+$.

(2*R*,3*S*,4*S*,5*S*)-3,4-Dihydroxy-3,4-*O*-isopropylidene-2-((*R*)-1,2-dihydroxy-1,2-*O*-isopropylidene)ethyl)-1,6-dioxo-spiro[4.5]-dec-8-ene (27). Obtained from **26** by RCM according to the general procedure (method A) as a colourless syrup (0.48 g, 1.54 mmol, 87%); $[\alpha]_{\text{D}}^{25} + 58.2$ (c 1 in CHCl_3); δ_{H} (300 MHz; CDCl_3 ; Me_4Si) 5.72 (br s, 2H, H-8,9), 4.82 (dd, 1H, J 3.6 and 5.8 Hz, H-3), 4.43 (d, 1H, J 5.8 Hz, H-4), 4.35–4.40 (m, 1H, CH_2 Et), 3.95–4.18 (m, 4H, $2 \times$ H-7 and CH and CH_2 Et), 3.85 (dd, 1H, J 3.7 and 8.0 Hz, H-2), 2.50 (dd, 1H, J 1.5 and 19 Hz, H-10), 2.12 (dd, 1H, J 2.2 and 17.5 Hz, H-10), 1.33, 1.36, 1.44 and 1.46 (4s, each 3H, CH_3); δ_{C} (50 MHz; CDCl_3 ; Me_4Si) 124.2 (C-8), 121.6 (C-9), 108.9 and 112.1 (C_q), 104.6 (C-5), 72.8, 79.3, 79.8 and 85.5 (C-2,3,4 and CH Et), 67.0 (CH_2 Et), 59.8 (C-7), 28.6 (C-10), 24.4, 24.9, 25.7 and 26.6 (CH_3); MS (ESI): calc. for $\text{C}_{16}\text{H}_{24}\text{O}_6$ 312.2, found m/z 335.2 ($\text{M} + \text{Na}$) $^+$.

3-Buten-1-yl (1,2,3-trideoxy-5,6;8,9-di-*O*-isopropylidene)- α -D-manno-non-1-eno-4-ulofuranose (28). Prepared from **25** by K-10-mediated glycosidation according to the general procedure. Colourless syrup (0.30 g, 0.85 mmol, 42%); δ_{H} (200 MHz; CDCl_3 ; Me_4Si) 5.68–5.81 (m, 2H, H-2 and CH Bu), 5.00–5.19 (m, 4H, $2 \times$ H-1 and CH_2 Bu), 4.79 (dd, 1H, J 4.4 and 5.8 Hz, H-6), 4.43 (d, 1H, J 5.8 Hz, H-5), 4.32–4.39 (m, 1H, H-8), 4.10 (dd, 1H, J 6.6 and 8.8 Hz, H-9), 3.97 (dd, 1H, J 4.4 and 8.8 Hz, H-9), 3.80 (dd, 1H, J 3.7 and 8.0 Hz, H-7), 3.47 (br t, 2H, J 6.6 Hz, CH_2 Bu), 2.56–2.61 (m, 2H, $2 \times$ H-3), 2.50 (dd, 2H, J 6.6 and 13.1 Hz, CH_2 Bu), 1.32, 1.37, 1.45 and 1.47 (4s, each 3H, CH_3); δ_{C} (50 MHz; CDCl_3 ; Me_4Si) 135.3 (CH Bu), 132.3 (C-2), 117.6 (C-1), 116.4 (CH_2 Bu), 112.3 (C-4), 108.7 and 109.0 (C_q), 72.9, 79.0, 79.9 and 84.6 (C-5,6,7,8), 66.9 (C-9), 59.6 (CH_2 Bu), 34.1 (C-3), 34.0 (CH_2 Bu), 24.4, 25.1, 25.8 and 26.7 (CH_3); MS (ESI): calc. for $\text{C}_{19}\text{H}_{30}\text{O}_6$ 354.2, found m/z 377.2 ($\text{M} + \text{Na}$) $^+$.

(2*R*,3*S*,4*S*,5*S*)-3,4-Dihydroxy-3,4-*O*-isopropylidene-2-((*R*)-1,2-dihydroxy-1,2-*O*-isopropylidene)ethyl)-1,6-dioxo-spiro[4.6]-undec-9-ene (29). Obtained from **28** by RCM according to the general procedure (method B) as a greenish syrup (0.27 g, 0.83 mmol, 99%); $[\alpha]_{\text{D}}^{25} + 9.2$ (c 1 in CHCl_3); δ_{H} (600 MHz; CDCl_3 ; Me_4Si) 5.65 (m, 1H, H-9), 5.53 (m, 1H, H-10), 4.74 (dd, 1H, J 3.8 and 5.9 Hz, H-3), 4.36 (d, 1H, J 5.9 Hz, H-4), 4.29–4.32

(m, 1H, CH Et), 4.03 (dd, 1H, J 6.3 and 8.7 Hz, CH_2 Et), 3.94 (dd, 1H, J 4.3 and 8.7 Hz, CH_2 Et), 3.89 (dd, 1H, J 2.2 and 12.0 Hz, H-7), 3.75 (dd, 1H, J 3.8 and 8.2 Hz, H-2), 3.55 (dd, 1H, J 3.7 and 12.3 Hz, H-7), 2.66 (dd, 1H, J 6.5 and 16.3 Hz, H-11), 2.46 (dd, 1H, J 5.3 and 16.3 Hz, H-11), 2.38–2.43 (m, 1H, H-8), 2.17 (br d, 1H, J 17.2 Hz, H-8), 1.26, 1.31, 1.38 and 1.42 (4s, each 3H, CH_3); δ_{C} (50 MHz; CDCl_3 ; Me_4Si) 130.0 (C-10), 124.3 (C-9), 112.3 (C_q), 108.9 (C-5), 72.9, 78.6, 79.9 and 85.4 (C-2,3,4 and CH Et), 67.1 (CH_2 Et), 60.4 (C-7), 31.8 (C-11), 31.1 (C-8), 24.3, 25.0, 25.7 and 26.7 (CH_3); MS (ESI): calc. for $\text{C}_{17}\text{H}_{26}\text{O}_6$ 326.2, found m/z 349.1 ($\text{M} + \text{Na}$) $^+$.

(1*R*,3*R*,4*R*,5*S*,6*R*)-4,5-Bis-benzyloxy-3-hydroxy-3-vinyl-2,7-dioxo-bicyclo[4.4.0]dec-9-ene (32). Bicyclic methyl glycoside **30**²² (630 mg, 1.7 mmol) was dissolved in acetic acid (20 ml) and 3 M sulfuric acid (2.4 ml). The mixture was stirred at 80 °C for 6 h, then allowed to cool to room temperature and diluted with ethyl acetate (30 ml). The organic phase was washed with sat. NaHCO_3 until pH 7, dried, filtered and concentrated. The residue was purified by silica gel chromatography (15% EtOAc–light petroleum ether). The purified lactol was dissolved in dimethylsulfoxide–acetic anhydride 2 : 1 v/v (6 ml) and stirred for 17 h, when TLC analysis (25% EtOAc–light petroleum ether) revealed complete consumption of the starting material. The mixture was concentrated, dissolved in ethyl acetate and extracted with sat. NaHCO_3 . Organics were dried, filtered and concentrated to leave a brown syrup (300 mg, 0.8 mmol, 50%), which was subjected to a Grignard reaction with vinylmagnesium bromide as described in the general procedure to give **32** as a colourless syrup (117 mg, 0.30 mmol, 21%); δ_{H} (200 MHz; CDCl_3 ; Me_4Si) 7.26–7.31 (m, 10H, CH_{arom}), 5.89 (dd, 1H, J 10.2 and 17 Hz, CH vinyl), 5.68–5.77 (m, 2H, H-9,10), 5.59 (dd, 1H, J 1.5 and 16.8 Hz, CH_2 vinyl), 5.28 (dd, 1H, J 1.5 and 10.2 Hz, CH_2 vinyl), 4.61, 4.77, 4.82 and 4.98 (4d, each 1H, CH_2 Bn), 4.48 (m, 1H, H-1), 4.25 (br s, 2H, $2 \times$ H-8), 3.89 (dd, 1H, J 8.8 and 9.5 Hz, H-5), 3.43 (d, 1H, J 8.8 Hz, H-4), 3.33 (dd, 1H, J 8.8 and 9.5 Hz, H-6); δ_{C} (50 MHz; CDCl_3 ; Me_4Si) 138.8 (CH vinyl), 127.7–128.7 (C-9 and CH_{arom}), 126.1 (C-10), 117.0 (CH_2 vinyl), 96.2 (C-3), 65.1, 78.8, 80.5 and 82.7 (C-1,4,5,6), 74.9 and 75.8 (CH_2 Bn), 66.0 (C-8); MS (ESI): calc. for $\text{C}_{24}\text{H}_{26}\text{O}_5$ 394.2, found m/z 417.3 ($\text{M} + \text{Na}$) $^+$.

(1*R*,3*R*,4*R*,5*S*,6*R*)-3-Allyloxy-4,5-bis-benzyloxy-3-vinyl-2,7-dioxo-bicyclo[4.4.0]dec-9-ene (33). Prepared from **32** by K-10-mediated glycosidation according to the general procedure. Colourless syrup (65 mg, 0.15 mmol, 50%); δ_{H} (200 MHz; CDCl_3 ; Me_4Si) 7.22–7.40 (m, 10H, CH_{arom}), 5.73–6.00 (m, 2H, CH vinyl and allyl), 5.52 (dd, 1H, J 2.2 and 17.5 Hz, CH_2 allyl), 5.27 (dd, 1H, J 1.5 and 16.8 Hz, CH_2 vinyl), 5.26 (dd, 1H, J 2.2 and 11.0 Hz, CH_2 allyl), 5.12 (dd, 1H, J 1.5 and 10.2 Hz, CH_2 vinyl), 4.62, 4.78, 4.91 and 4.96 (4d, each 1H, CH_2 Bn), 4.26 (br s, 2H, $2 \times$ H-8), 4.18 (m, 1H, H-1), 4.06 (dd, 1H, J 8.8 and 9.5 Hz, H-5), 3.94 (m, 2H, CH_2 allyl), 3.35 (d, 1H, J 8.8 Hz, H-4), 3.31 (dd, 1H, J 8.8 and 9.5 Hz, H-6); MS (ESI): calc. for $\text{C}_{27}\text{H}_{30}\text{O}_5$ 434.2, found m/z 457.2 ($\text{M} + \text{Na}$) $^+$.

(1*R*,3*S*,4*R*,5*S*,6*R*)-4,5-Bis-benzyloxy-2,7-dioxo-bicyclo[4.4.0]-dec-9-enylspiro-3,2'-[2',5'-dihydrofuran] (34). Obtained from **33** by RCM according to the general procedure (method B) as a greenish syrup (58 mg, 0.14 mmol, 95%); δ_{H} (300 MHz; CDCl_3 ; Me_4Si) 7.20–7.29 (m, 10H, CH_{arom}), 6.26 (m, 1H, H-3'), 5.77 (m, 2H, H-9,10), 5.55 (m, 1H, H-4'), 4.77 (br s, 2H, $2 \times$ H-5'), 4.59, 4.80 and 4.98 (3d, 4H, CH_2 Bn), 4.40 (m, 1H, H-1), 4.26 (m, 2H, $2 \times$ H-8), 3.97 (br t, 1H, J 9.5 Hz, H-6), 3.61 (d, 1H, J 8.8 Hz, H-4), 3.33 (dd, 1H, J 8.8 and 9.5 Hz, H-5); δ_{C} (50 MHz; CDCl_3 ; Me_4Si) 138.1 and 138.9 (C_q Bn), 132.6 (C-3'), 126.1–128.1 (C-4',9,10 and CH_{arom}), 112.8 (C-3), 78.9, 80.8 and 81.2 (C-4,5,6), 75.1 and 75.9 (CH_2 Bn), 66.1 (C-8), 66.0 (C-1); MS (ESI): calc. for $\text{C}_{25}\text{H}_{26}\text{O}_5$ 406.2, found m/z 429.1 ($\text{M} + \text{Na}$) $^+$.

3-*O*-(4',5',6',8'-Tetra-*O*-benzyl-1',2'-dideoxy- α -D-glucopyranosyl)-5,6-dideoxy-1,2-*O*-isopropylidene- α -D-xylohex-5-enofuranoside (36). K-10 mediated glycosidation, as described in the general procedure, of **2** (0.39 g, 0.68 mmol) with 5,6-dideoxy-1,2-*O*-isopropylidene- α -D-xylohex-5-enofuranose²² (**35**, 0.76 g, 4.09 mmol) afforded **36** as a colourless syrup (0.23 g, 0.31 mmol, 45%); δ_{H} (200 MHz; CDCl₃; Me₄Si) 7.18–7.35 (m, 20H, CH_{arom}), 6.21 (m, 1H, H-5), 5.95 (dd, 1H, *J* 11.0 and 17.5 Hz, H-2'), 5.93 (dd, 1H, *J* 2.2 and 12.4 Hz, H-6), 5.64 (dd, 1H, *J* 2.2 and 17.5 Hz, H-6), 5.38 (d, 1H, *J* 2.9 Hz, H-1), 5.31–5.39 (m, 1H, H-1), 5.17 (dd, 1H, *J* 1.5 and 10.2 Hz, H-1), 4.52–4.91 (m, 10H, H-3,4 and CH₂ Bn), 4.26 (d, 1H, *J* 2.9 Hz, H-2), 4.07 (t, 1H, *J* 9.5 Hz, H-5'), 3.94 (m, 1H, H-8'), 3.63–3.82 (m, 2H, H-7',8'), 3.53 (t, 1H, *J* 9.5 Hz, H-6'), 3.30 (d, 1H, *J* 9.5 Hz, H-4'), 1.18 and 1.47 (2s, each 3H, CH₃); δ_{C} (50 MHz; CDCl₃; Me₄Si) 137.9 and 138.5 (C_q Bn), 133.2 and 135.0 (C-2',5), 127.1–128.4 (CH_{arom}), 119.5 and 119.7 (C-1',6), 111.2 (C_q), 104.7 (C-1), 100.5 (C-3'), 73.5, 75.2, 75.4 and 75.6 (CH₂ Bn), 72.5, 78.4, 78.6, 82.3, 82.5, 83.6 and 85.1 (C-2,3,4,4',5',6',7'), 69.1 (C-8'), 26.0 and 26.7 (CH₃); MS (ESI): calc. for C₄₅H₅₀O₉, 734.3, found *m/z* 757.4 (M + Na)⁺.

2,3,4,6-Tetra-*O*-benzyl- α -D-glucopyranosylspiro-1'-[(3',5',4',5',7',7')-4',5'-dihydroxy-4',5'-*O*-isopropylidene-2',6'-dioxabicyclo[3.4.0]non-8'-ene] (37). Obtained from **36** by RCM according to the general procedure (method B) as a colourless syrup (85 mg, 0.12 mmol, 64%); $[\alpha]_{\text{D}}^{25} + 64.4$ (*c* 1 in CHCl₃); δ_{H} (300 MHz; CDCl₃; Me₄Si) 7.12–7.31 (m, 20H, CH_{arom}), 6.18 (dd, 1H, *J* 5.1 and 10.2 Hz, H-9'), 6.08 (d, 1H, *J* 3.6 Hz, H-1), 5.78 (d, 1H, *J* 10.2 Hz, H-8'), 4.69 (br s, 2H, CH₂ Bn), 4.47, 4.53, 4.60, 4.81, 4.83 and 4.91 (6d, each 1H, CH₂ Bn), 4.40 (m, 1H, H-5'), 4.29 (d, 1H, *J* 3.0 Hz, H-4'), 4.05 (t, 1H, *J* 8.8 Hz, H-3), 3.61–3.88 (m, 4H, H-1,7 and 2 × H-8), 3.71 (t, 1H, *J* 8.8 Hz, H-4), 3.51 (d, 1H, *J* 8.8 Hz, H-2), 1.32 and 1.52 (2s, each 3H, CH₃); δ_{C} (50 MHz; CDCl₃; Me₄Si) 137.9, 138.1 and 138.7 (C_q Bn), 127.7–128.3 (CH_{arom}), 125.4 and 132.2 (C-8',9'), 111.3 (C_q), 105.7 (C-3'), 95.5 (C-1'), 73.4, 74.7, 74.9 and 75.5 (CH₂ Bn), 69.5, 71.8, 73.7, 77.8, 82.6 and 84.2 (C-1',2,3,4,4',5,5'), 68.3 (C-6), 26.1 and 26.8 (CH₃); MS (ESI): calc. for C₄₃H₄₆O₉, 706.3, found *m/z* 729.5 (M + Na)⁺.

(2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-Tris-benzyloxy-2-benzyloxymethyl-1,7-dioxaspiro[5.5]undec-8-ene (38). To a stirred solution of **8** (330 mg, 0.56 mmol) in anhydrous ethanol (30 mL) were added Wilkinson's catalyst (129 mg, 0.13 mmol) and DBU (2 drops) under a nitrogen atmosphere. The mixture was heated to 60 °C for 1 h after which TLC analysis (25% EtOAc–light petroleum ether) revealed completed conversion. The mixture was allowed to cool to room temperature and concentrated. Silica gel chromatography (15% EtOAc–light petroleum ether) of the residue yielded **38** as a colourless syrup (296 mg, 0.50 mmol, 90%); $[\alpha]_{\text{D}}^{25} + 8.4$ (*c* 1 in CHCl₃); δ_{H} (200 MHz; CDCl₃; Me₄Si) 7.16–7.26 (m, 20H, CH_{arom}), 6.25 (d, 1H, *J* 6.2 Hz, H-8), 4.50, 4.55, 4.57, 4.60, 4.68, 4.86, 4.91 and 4.92 (8d, each 1H, CH₂ Bn), 4.79 (m, 1H, H-9), 4.16 (t, 1H, *J* 9.1 Hz, H-4), 4.11–4.21 (m, 1H, CH₂OBn), 3.62–3.79 (m, 3H, H-2,3 and CH₂OBn), 3.40 (d, 1H, *J* 9.9 Hz, H-5), 1.49–2.05 (m, 4H, 2 × H-10 and 2 × H-11); δ_{C} (50 MHz; CDCl₃; Me₄Si) δ 139.6 (C-8), 137.7, 138.2 and 138.6 (C_q Bn), 127.5–128.4 (CH_{arom}), 102.3 (C-9), 97.6 (C-6), 71.8, 78.3, 82.6 and 83.0 (C-2,3,4,5), 73.1, 74.8, 75.5 and 75.6 (CH₂ Bn), 68.4 (CH₂OBn), 26.8 (C-11), 16.0 (C-10); MS (ESI): calc. for C₃₈H₄₀O₆, 592.3, found *m/z* 615.3 (M + Na)⁺.

(2*R*,3*R*,4*S*,5*R*,6*S*,8*R*,9*S*)-8-Allyl-3,4,5-tris-benzyloxy-2-benzyloxymethyl-1,7-dioxaspiro[5.5]undecan-9-ol (39). To a chilled (0 °C) solution of spiroketal **38** (370 mg, 0.63 mmol) in anhydrous dichloromethane (3 mL) was added dropwise a freshly prepared solution of 3,3-dimethyldioxirane (9 mL, 0.09 M, 0.8 mmol) in acetone.²⁵ After stirring the mixture for

10 min, TLC analysis (20% EtOAc–light petroleum ether) showed complete consumption of the starting material. The mixture was concentrated, redissolved in anhydrous toluene (5 mL) and concentrated again. The crude epoxide was dissolved in THF (5 mL), cooled to 0 °C under argon atmosphere, after which a solution of allylmagnesium chloride (0.58 mL, 2 M, 1.16 mmol) was added. After stirring for 15 min., TLC analysis (33% EtOAc/light petroleum ether) showed a nearly completed reaction. The reaction was quenched by addition of sat. NH₄Cl and extracted with diethyl ether. The organic layer was washed with sat. NH₄Cl, dried and concentrated. Silica gel chromatography (16 to 40% EtOAc–light petroleum ether) yielded compound **39** as a colourless syrup (246 mg, 0.37 mmol, 61%); δ_{C} (50 MHz; CDCl₃; Me₄Si) 137.7, 138.1 and 138.5 (C_q Bn), 134.8 (CH allyl), 127.4–128.2 (CH_{arom}), 117.1 (CH₂ allyl), 98.3 (C-6), 73.2, 74.8, 75.3 and 75.7 (CH₂ Bn), 68.7 (CH₂OBn), 65.9, 71.1, 77.9, 78.5, 82.9 and 83.7 (C-2,3,4,5,8,9), 37.4 (CH₂ allyl), 25.0 (C-11), 21.8 (C-10); MS (ESI): calc. for C₄₁H₄₆O₇, 650.3, found *m/z* 673.3 (M + Na)⁺.

(2*R*,3*R*,4*S*,5*R*,6*S*,8*R*,9*S*)-8-Allyl-9-allyloxy-3,4,5-tris-benzyloxy-2-benzyloxymethyl-1,7-dioxaspiro[5.5]undecane (40). To a solution of compound **39** (246 mg, 0.38 mmol) in anhydrous *N,N*-dimethylformamide (3 mL) were added allyl bromide (50 μ l, 0.57 mmol) and sodium hydride (20 mg, 60% dispersion in oil, 0.49 mmol). After stirring for 16 h, TLC analysis (33% EtOAc–light petroleum ether) showed complete disappearance of **39**. The excess sodium hydride was destroyed by addition of methanol (5 mL). The mixture was partitioned between diethyl ether and brine. The organic phase was extracted with brine, dried and concentrated. Purification was effected by silica gel chromatography (20% EtOAc–light petroleum ether) to afford **40** as a colourless syrup (242 mg, 0.35 mmol, 93%); δ_{C} (50 MHz; CDCl₃; Me₄Si) 138.2 and 138.7 (C_q Bn), 135.1 (CH allyl), 127.3–128.2 (CH_{arom}), 116.1 and 116.9 (CH₂ allyl), 98.6 (C-6), 73.1, 74.7, 75.3 and 75.5 (CH₂ Bn), 70.9, 72.9, 75.4, 78.6, 82.9 and 84.0 (C-2,3,4,5,8,9), 69.1 (CH₂ allyl), 68.8 (CH₂OBn), 37.6 (CH₂ allyl), 25.5 (C-11), 19.4 (C-10); MS (ESI): calc. for C₄₄H₅₀O₇, 690.3, found *m/z* 713.3 (M + Na)⁺.

2,3,4,6-Tetra-*O*-benzyl- α -D-glucopyranosylspiro-3'-[(1'*R*,6'*S*)-2',7'-dioxabicyclo[4.5.0]undec-9'-ene] (42). To a solution of diene **40** (240 mg, 0.35 mmol) in anhydrous dichloromethane (5 mL) was added Grubbs' catalyst **41**²⁷ (0.1 mg, 0.18 μ mol) under argon atmosphere and the mixture was stirred at 40 °C for 2 h. TLC analysis (33% EtOAc–light petroleum ether) revealed a completed conversion, after which the mixture was concentrated and purified by silica gel chromatography (20% EtOAc–light petroleum ether) to give a colourless syrup of **42** (185 mg, 0.28 mmol, 80%); δ_{H} (300 MHz; CDCl₃; Me₄Si) 7.16–7.31 (m, 20H, CH_{arom}), 5.76–5.86 (m, 2H, H-9',10'), 4.88 (br s, 2H, CH₂ Bn), 4.51, 4.54, 4.60, 4.67, 4.84 and 4.89 (6d, each 1H, CH₂ Bn), 4.14 (d, 1H, *J* 4.9 and 14.7 Hz, H-8'), 4.04 (t, 1H, *J* 9.2 Hz, H-3), 3.84–4.01 (m, 1H, H-8'), 3.57–3.76 (m, 5H, H-1,4,5 and 2 × H-6), 3.33 (d, 1H, *J* 9.5 Hz, H-2), 2.61–2.69 (m, 1H, H-11'), 2.11–2.33 (m, 3H, H-4',5',11'), 1.42–1.83 (m, 2H, H-4',5'); δ_{C} (50 MHz; CDCl₃; Me₄Si) 137.9, 138.1, 138.2 and 138.6 (C_q Bn), 131.7 and 131.9 (C-9',10'), 127.4–128.8 (CH_{arom}), 98.6 (C-1), 73.2, 74.9 and 75.4 (CH₂ Bn), 70.7, 73.4, 78.6, 81.0, 83.3 and 83.7 (C-1',2,3,4,5,6'), 68.9 (C-6), 67.1 (C-8'), 34.3 (C-11'), 27.5 (C-4'), 24.8 (C-5'); MS (ESI): calc. for C₄₂H₄₆O₇, 662.3, found *m/z* 685.3 (M + Na)⁺.

Acknowledgements

The authors thank Fons Lefeber for recording the nOe-difference spectra, and Hans van den Elst and Nico Meeuwenoord for recording the mass spectra. H.S.O. thanks the Netherlands Organization for Scientific Research (NWO) for financial support.

References and notes

- 1 For reviews on the synthesis of spiroketals, see: (a) F. Perron and K. F. Albizzati, *Chem. Rev.*, 1989, **89**, 1617; (b) T. L. B. Boivin, *Tetrahedron*, 1987, **43**, 3309; (c) A. F. Kluge, *Heterocycles*, 1986, **24**, 1699; (d) I. E. Markó, A. Mekhalfia, F. Murphy, D. J. Bayston, M. Bailey, Z. Janousek and S. Dolan, *Pure Appl. Chem.*, 1997, **69**, 565.
- 2 S. Hanessian and A. Ugolini, *Carbohydr. Res.*, 1984, **130**, 261.
- 3 (a) I. I. Cubero, M. T. P. López-Espinosa and N. Kari, *Carbohydr. Res.*, 1995, **268**, 187; (b) I. I. Cubero, M. T. P. López-Espinosa and N. Kari, *Carbohydr. Res.*, 1994, **261**, 231; (c) I. I. Cubero, M. T. P. López-Espinosa, A. C. Richardson and K. H. Aamlid, *Carbohydr. Res.*, 1993, **242**, 281.
- 4 (a) R. L. Dorta, A. Martín, J. A. Salazar and E. Suárez, *J. Org. Chem.*, 1998, **63**, 2251; (b) R. L. Dorta, A. Martín, J. A. Salazar and E. Suárez, *Tetrahedron Lett.*, 1996, **37**, 6021; (c) A. Martín, J. A. Salazar and E. Suárez, *J. Org. Chem.*, 1996, **61**, 3999; (d) A. Martín, J. A. Salazar and E. Suárez, *Tetrahedron Lett.*, 1995, **36**, 4489.
- 5 A. Haudrechy and P. Sinaÿ, *Carbohydr. Res.*, 1991, **216**, 375.
- 6 A synthesis of carbohydrate-derived spiroketals, analogous to reference 5, was recently published: G. V. M. Sharma, Rakesh, A. S. Chander, V. G. Reddy, M. V. H. R. Rao and A. C. Kunwar, *Tetrahedron: Asymmetry*, 2003, **14**, 2991.
- 7 (a) P. A. V. van Hoof, M. A. Leeuwenburgh, H. S. Overkleeft, G. A. van der Marel, C. A. A. van Boeckel and J. H. van Boom, *Tetrahedron Lett.*, 1998, **39**, 6061; (b) M. A. Leeuwenburgh, C. C. M. Appeldoorn, P. A. V. van Hoof, H. S. Overkleeft, G. A. van der Marel and J. H. van Boom, *Eur. J. Org. Chem.*, 2000, 873.
- 8 B. M. Trost and E. D. Edstrom, *Angew. Chem., Int. Ed. Engl.*, 1990, **29**, 520.
- 9 P. Schwab, R. H. Grubbs and J. W. Ziller, *J. Am. Chem. Soc.*, 1996, **118**, 100.
- 10 Assignment according to the CIP system: H. Hirschmann and K. R. Hanson, *J. Org. Chem.*, 1971, **36**, 3293.
- 11 Previous assignment of absolute configuration at the spirocentre in this compound was incorrect, see references 5 and 10.
- 12 H. Kuzuhara and H. G. Fletcher, *J. Am. Chem. Soc.*, 1967, **73**, 2531.
- 13 K. Tomooka, Y. Nakamura and T. Nakai, *Synlett*, 1995, 321.
- 14 M. D. Lewis, J. K. Cha and Y. Kishi, *J. Am. Chem. Soc.*, 1982, **104**, 4976.
- 15 The absolute configurations at the spirocentres of all compounds described in this paper were determined by NOESY-experiments.
- 16 M. L. Alcaraz, F. K. Griffin, D. E. Paterson and R. J. K. Taylor, *Tetrahedron Lett.*, 1998, **39**, 8183.
- 17 The synthesis of compound **11** via a different approach was recently reported: R. Caputo, U. Ciriello, P. Festa, A. Guaragna, G. Palumbo and S. Pedatella, *Eur. J. Org. Chem.*, 2003, 2617.
- 18 S. Cai, M. R. Stroud, S. Hakomori and T. Toyokuni, *J. Org. Chem.*, 1992, **57**, 6693.
- 19 A. J. Norris and T. Toyokuni, *J. Carbohydr. Chem.*, 1999, **18**, 1097.
- 20 R. S. Tipson, H. S. Isbell and J. E. Stewart, *J. Res. Natl. Bur. Stand.*, 1959, **62**, 257.
- 21 Similar bis-adducts have been isolated after Grignard reactions with γ -valerolactone and δ -butyrolactone; see: (a) H. Ogura, H. Takahashi and Itoh, *J. Org. Chem.*, 1972, **37**, 72; (b) M. Sprinzl, J. Farkas and F. Šorm, *Tetrahedron Lett.*, 1966, 597; (c) M. S. Kharash in *Grignard Reactions of Non-Metallic Substances*, Prentice Hall, Englewood Cliffs, New York, 1954, and references cited herein.
- 22 (a) M. A. Leeuwenburgh, H. S. Overkleeft, G. A. van der Marel and J. H. van Boom, *Synlett*, 1997, 1263; (b) M. A. Leeuwenburgh, C. Kulker, H. I. Duynstee, H. S. Overkleeft, G. A. van der Marel and J. H. van Boom, *Tetrahedron*, 1999, **55**, 8253–8262.
- 23 G. V. M. Sharma and K. Krishnu, *Tetrahedron Lett.*, 1995, **36**, 2661.
- 24 (a) E. J. Corey and J. W. Suggs, *J. Org. Chem.*, 1973, **38**, 3224; (b) J. S. Clark and J. G. Kettle, *Tetrahedron Lett.*, 1997, **38**, 127.
- 25 W. Adam, J. Bialas and L. Hadjarapoglou, *Chem. Ber.*, 1991, 2377.
- 26 (a) W. M. Best, V. Ferro, J. Harle, R. V. Stick and D. M. G. Tilbrook, *Aust. J. Chem.*, 1997, **50**, 463; (b) D. A. Evans, B. W. Trotter and B. Côté, *Tetrahedron Lett.*, 1998, **39**, 1709.
- 27 M. Scholl, S. Ding, C. W. Ling and R. H. Grubbs, *Org. Lett.*, 2000, **2**, 953.
- 28 S. P. Allwein, J. M. Cox, B. E. Howard, H. W. B. Johnson and J. D. Rainier, *Tetrahedron*, 2002, **58**, 1997.